StemCo Biomedical, established in 1999, is a biotechnology company based in the Research Triangle Park area of NC. The company's focus lies in creating, manufacturing, and distributing medical products aimed at enhancing therapeutic transplantation of adult hematopoietic stem and progenitor cells. StemCo targets a market exceeding $1 billion annually and plans to introduce a series of products starting in 2002 that identify, sort, and custom-engineer stem cell grafts based on cellular expression of ALDH. This approach holds the potential to result in more effective stem cell transplants in the future.
The company recently received a $9.80M Series B investment on 18 March 2003 from a group of investors including Intersouth Partners, Tall Oaks Capital, The Trelys Funds, Becton Dickinson India, and The Aurora Funds.
StemCo's efforts to redefine the future of therapeutic transplants through advanced stem cell grafts position it at the forefront of innovation in the biotechnology industry. With a strong track record and a clear focus on addressing a significant market need, the company has garnered the support of notable investors, signaling strong potential for future growth and impact within the sector.
